Literature DB >> 24217816

Allogeneic bone marrow transplantation appears to ameliorate IgA nephropathy in a patient with X-linked thrombocytopenia.

Akihiro Hoshino1, Masaki Shimizu, Hiroyoshi Matsukura, Hisano Sakaki-Nakatsubo, Keiko Nomura, Toshio Miyawaki, Hirokazu Kanegane.   

Abstract

Wiskott-Aldrich syndrome (WAS) is caused by a mutation in the WAS gene, and it is clinically characterized by the triad of thrombocytopenia, eczema and immunodeficiency. X-linked thrombocytopenia (XLT), which is a clinically mild form of WAS, is also caused by a WAS gene mutation. Patients with WAS/XLT sometimes also have autoimmune diseases such as IgA nephropathy. Progression of IgA nephropathy may lead to chronic renal failure with a poor prognosis. Here, we describe an XLT patient who also had IgA nephropathy. The patient underwent bone marrow transplantation (BMT) because of an associated-lymphoproliferative disorder, and clinical and histological improvement in his IgA nephropathy was observed after BMT. The amount of galactose-deficient IgA in the patient's serum markedly decreased after BMT. Therefore, immunological reconstitution might improve autoimmune diseases in patients with WAS/XLT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24217816     DOI: 10.1007/s10875-013-9964-4

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  25 in total

1.  Development of IgA nephropathy-like glomerulonephritis associated with Wiskott-Aldrich syndrome protein deficiency.

Authors:  M Shimizu; N P Nikolov; K Ueno; K Ohta; R M Siegel; A Yachie; F Candotti
Journal:  Clin Immunol       Date:  2011-10-19       Impact factor: 3.969

2.  X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options.

Authors:  Michael H Albert; Tanja C Bittner; Shigeaki Nonoyama; Lucia Dora Notarangelo; Siobhan Burns; Kohsuke Imai; Teresa Espanol; Anders Fasth; Isabelle Pellier; Gabriele Strauss; Tomohiro Morio; Benjamin Gathmann; Jeroen G Noordzij; Cristina Fillat; Manfred Hoenig; Michaela Nathrath; Alfons Meindl; Philipp Pagel; Uwe Wintergerst; Alain Fischer; Adrian J Thrasher; Bernd H Belohradsky; Hans D Ochs
Journal:  Blood       Date:  2010-02-19       Impact factor: 22.113

3.  Disappearance of mesangial IgA deposits from the kidneys of two donors after transplantation.

Authors:  X Cuevas; J Lloveras; M Mir; J Aubia; J Masramon
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

4.  Bone marrow transplantation attenuates murine IgA nephropathy: role of a stem cell disorder.

Authors:  T Imasawa; R Nagasawa; Y Utsunomiya; T Kawamura; Y Zhong; N Makita; E Muso; S Miyawaki; N Maruyama; T Hosoya; O Sakai; T Ohno
Journal:  Kidney Int       Date:  1999-11       Impact factor: 10.612

Review 5.  Mechanism of onset and exacerbation of chronic glomerulonephritis and its treatment.

Authors:  Yukihiko Kawasaki
Journal:  Pediatr Int       Date:  2011-11-10       Impact factor: 1.524

6.  Aberrant glycosylation of IgA in Wiskott-Aldrich syndrome and X-linked thrombocytopenia.

Authors:  Masaki Shimizu; Hirokazu Kanegane; Taizo Wada; Yaeko Motoyoshi; Tomohiro Morio; Fabio Candotti; Akihiro Yachie
Journal:  J Allergy Clin Immunol       Date:  2012-10-26       Impact factor: 10.793

7.  Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation.

Authors:  Hulya Ozsahin; Marina Cavazzana-Calvo; Luigi D Notarangelo; Ansgar Schulz; Adrian J Thrasher; Evelina Mazzolari; Mary A Slatter; Francoise Le Deist; Stephane Blanche; Paul Veys; Anders Fasth; Robbert Bredius; Petr Sedlacek; Nico Wulffraat; Juan Ortega; Carsten Heilmann; Anne O'Meara; Jacek Wachowiak; Krzysztof Kalwak; Susanne Matthes-Martin; Tayfun Gungor; Aydan Ikinciogullari; Paul Landais; Andrew J Cant; Wilhelm Friedrich; Alain Fischer
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

8.  Toll-like receptor 9 affects severity of IgA nephropathy.

Authors:  Hitoshi Suzuki; Yusuke Suzuki; Ichiei Narita; Masashi Aizawa; Masao Kihara; Takahiro Yamanaka; Tatsuya Kanou; Hiroyasu Tsukaguchi; Jan Novak; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Am Soc Nephrol       Date:  2008-09-05       Impact factor: 10.121

9.  IgA nephropathy associated with X-linked thrombocytopenia.

Authors:  Hiro Matsukura; Hirokazu Kanegane; Kazushi Miya; Keisuke Ohtsubo; Akira Higuchi; Takakuni Tanizawa; Toshio Miyawaki
Journal:  Am J Kidney Dis       Date:  2004-03       Impact factor: 8.860

10.  X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene.

Authors:  A Villa; L Notarangelo; P Macchi; E Mantuano; G Cavagni; D Brugnoni; D Strina; M C Patrosso; U Ramenghi; M G Sacco
Journal:  Nat Genet       Date:  1995-04       Impact factor: 38.330

View more
  3 in total

1.  The clinical features of autoimmunity in 53 patients with Wiskott-Aldrich syndrome in China: a single-center study.

Authors:  Nan Chen; Zhi-Yong Zhang; Da-Wei Liu; Wei Liu; Xue-Mei Tang; Xiao-Dong Zhao
Journal:  Eur J Pediatr       Date:  2015-04-16       Impact factor: 3.183

2.  Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene.

Authors:  Koichi Oshima; Kohsuke Imai; Michael H Albert; Tanja C Bittner; Gabriele Strauss; Alexandra H Filipovich; Tomohiro Morio; Neena Kapoor; Jignesh Dalal; Kirk R Schultz; James T Casper; Luigi D Notarangelo; Hans D Ochs; Shigeaki Nonoyama
Journal:  J Clin Immunol       Date:  2014-11-12       Impact factor: 8.317

3.  Successful Induction of Specific Immunological Tolerance by Combined Kidney and Hematopoietic Stem Cell Transplantation in HLA-Identical Siblings.

Authors:  Thomas Fehr; Kerstin Hübel; Olivier de Rougemont; Irene Abela; Ariana Gaspert; Tayfun Güngör; Mathias Hauri; Birgit Helmchen; Claudia Linsenmeier; Thomas Müller; Jakob Nilsson; Oliver Riesterer; John D Scandling; Urs Schanz; Pietro E Cippà
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.